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Simmary First- and second-degree relatives of an unselected series of 402 breast cancer patients have been
studied for their cancer experience. In the first-degree relatives an excess of all cancers is seen [overall relative
risk (RR) = 1.28, P = 0002; males RR = 1.26, P = 0.047; females RR = 1.30, P= 0.022). There is a marked
excess of sarcoma (RR = 4.26, P = 0.0064); females are at high risk of breast cancer (RR = 2.68, P<0.0001)
and males have an excess of carcinoma of the lip, oral cavity and pharynx (RR = 4.22, P=0.0032).
Second-degree relatives have a non-significant excess of all cancers (RR = 1.14, P = 0.14); females have a
borderline excess of breast cancer (RR = 1.53, P = 0.08) and an excess of carcinoma of the kidney (RR = 7.46,
P= 0.0012) and males have an excess of carcinoma of the trachea and lung (RR = 1.50, P = 0.032). No excess
of prostate or ovarian carcinoma was seen. Relatives are at slightly higher risk if the index patient is diagnosed
between the ages of 40 and 49 (first-degree RR = 1.64, P= 0.007; second-degree RR = 1.43, P = 0.02). The
excess of cancers, including breast cancers, is not limited to a few high-risk families, but appears to be spread
across many. These observations may be accounted for by shared environmental factors within families or a
common predisposing gene with low penetrance.
Breast cancer is the most common cancer in females,
accounting for approximately 18% of all cancer in women
worldwide (Parkin et al., 1988). One of the strongest and
most consistently found risk factors for breast cancer is a
family history of the disease. Previous studies have compared
breast cancer patients with a family history with those with-
out, and found that the familial cases frequently have an
early age at onset and often suffer from bilateral disease
(Anderson, 1971, 1974; Anderson & Badzioch, 1985).
Segregation analyses of series of breast cancer patients and
their families have indicated that a proportion of breast
cancer may be due to inherited factors (Williams & Ander-
son, 1984; Newman et al., 1988; Claus et al., 1991). The
majority of segregation analyses have found that familial
breast cancer can best be explained by a rare dominant major
gene with high penetrance, but other studies have found that,
although this explains some of the clustering, different
models fit different groups of families (Andrieu et al., 1989).
Hall et al. (1990) found evidence for linkage of early-onset
familial breast cancer to a marker on chromosome 17q21.
Subsequent analyses of a large number of families have
defined more precisely the position of this gene (Hall et al.,
1992; Easton et al., 1993). Easton et al. (1993) found that, in
a series of 214 breast cancer families, all those which
included at least one case of ovarian cancer were consistent
with linkage to 17q21, while only 45% of families without
were tightly linked. They also found that the families which
demonstrated linkage to this region were those with many
cases of breast cancer, and most cases within linked families
were diagnosed at a young age. A higher proportion of the
families with average age at diagnosis under 45 years
appeared to be linked, with the proportion becoming smaller
as the average age at onset rises. The families included in
these linkage analyses were highly selected on the basis of
their striking family histories, and the relevance of the 17q
gene to breast cancer in general is not known.
More general studies of risks to relatives have concentrated
on young probands and breast cancer risks only. However,
two recent reports have found an excess of cancers of the
prostate, ovary, endometrium and cervix in the relatives of
breast cancer probands (Anderson et al., 1992; Tulinius et al.,
1992). The present study was designed to assess the incidence
of breast and other cancers, particularly prostate and ovary,
in the relatives of an unselected series of breast cancer
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patients to identify any specific associations and to provide
estimates of risk for counselling purposes. These issues have
not always been adequately addressed in previous studies
because of selection of the probands and the concentration
on site-specific breast cancer risks or consideration of mor-
tality only.
MateriaLs and methods
Ascertainent ofcases
Female patients were eligible for the study if they had been
diagnosed with a primary infiltrating carcinoma of the breast
between 1 June 1984 and 31 December 1986, and had re-
ceived surgery and other major treatment at Withington
Hospital and/or Christie Hospital, Manchester. Most of the
patients lived in south Manchester, but a small number lived
in other parts of the north-west region of England. This led
to a total of 474 eligible patients, who, with the consent of
their clinician, were approached for interview. Of these, 402
(85%) agreed to be interviewed, 29 refused, 14 were con-
sidered unfit for interview and 29 patients died soon after
diagnosis with advanced disease. These 402 patients were
interviewed and detailed information, including dates of
births and deaths, names, details of illnesses and treating
hospitals, was obtained for all their first- and second-degree
relatives. This enabled case records to be traced. The patient
was specifically asked about all relatives' diseases, and in
particular their cancer experience.
Family tracing and confirmation ofcancer reports
All the first-degree relatives of the interviewed patients living
in England and Wales were 'flagged' for cancer and death
notification at the National Health Service Central Register
(NHSCR) in Southport. Any report of cancer was verified, if
possible, by reference to medical records, including histology
reports, or by obtaining cancer registration details. If none of
these was available then death certificates were obtained.
Breast cancers in the patients and relatives were followed up
by obtaining histopathological material, which was reviewed
by one of us (M.H.).
Cases were classified as bilateral on the basis of differing
morphological appearance in the two tumours or the
presence of in situ elements in each. In the absence of in situ
elements when tumours were morphologically similar the case
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was classified as unilateral according to site at time of initial
diagnosis, and the second affected breast was regarded as
probable spread from the primary tumour. All neoplastic
disease was coded according to the International
Classification of Diseases for Oncology (WHO, 1976).
1976).
Statistical methods
As first-degree relatives are 'flagged', it is possible for us to
detect cancers that were not reported at interview or that
have occurred subsequent to the interview date. Information
on the first-degree relatives is generally more comprehensive
than on second-degree relatives. The two groups were
analysed in the same way but the results are reported separ-
ately. Expected numbers of cancers were calcuated from age-,
sex- and calendar period-specific cancer rates for the North
West Regional Cancer Registry. This registry was established
in 1963, and rates are considered reliable from 1970 (Nwene
& Smith, 1982). Thus, a person was considered to be 'at risk'
of cancer from 1 January 1965, or date of birth (whichever
was later), to date of death, 31 December 1988 for 'flagged'
relatives, date of last contact for unflagged relatives or 75th
birthday, whichever occurred first. Events over the period
1965-69 are compared with rates for 1970-74.
In all tables all cancers means any malignancy, except for
non-melanoma skin cancers, plus any tumour of the central
nervous system. Second and further primary cancers are
recorded by the cancer registry, so multiple primary cancers
in the relatives are also included in observed numbers.
Benign neoplasms, neoplasms of uncertain behaviour and in
situ cancers were not included in the analysis. These are
excluded because reporting to the Cancer Registry of non-
malignancies, or tumours which are not generally fatal, is
acknowledged to be less complete (Nwene & Smith, 1982).
Previous reports indicate that prostate cancer may be
associated with breast cancer in families. Since carcinoma of
the prostate, in general, is a late-onset cancer, we examined
the incidence of carcinoma at this site for all ages. In all
tables the totals are for cancers diagnosed at age less than 75,
but for carcinoma of the prostate all patients were included
regardless of age.
Observed numbers of cancer were compared with the
expected, and a two-sided Poisson probability calculated.
Relative risk ratios are estimated by dividing observed by
expected numbers of cancers, and 95% confidence intervals
calculated. All statistical analysis was done using Epilog Plus,
version 2 (1987).
Results
The 402 interviewed patients led to 399 families, as there
were two instances of sibling pairs and one instance of a
niece-aunt pair within the patient set. There were a total of
2,867 first-degree relatives. Complete information (i.e. date of
birth, age and status at last observation) was known on 2,630
of these, and 2,101 were at risk after 1 January 1965. Inform-
ation was available on 4,405 second-degree relatives; of these
3,275 were at risk after 1 January 1965.
For first-degree relatives, during the 'at-risk' time period,
165 cancers (153 of which were confirmed) were experienced
by 161 relatives. In 133 second-degree relatives a total of 136
cancers (107 of which were confirmed) were reported for the
same 'at-risk' period.
Overall cancer risk in the relatives is presented in Table I.
In the first-degree relatives there is a measurable excess for
both sexes. The second-degree relatives have an excess, but
this is not statistically significant. Table II shows the distribu-
tion of observed cancers by age group. Female first-degree
relatives have a marked excess of cancers in the 30-44 age
group. This is due to the excess of breast cancers. Male
first-degree relatives have an excess of cancers diagnosed
between ages 60 and 74. For second-degree relatives there is
a significant excess of cancers between ages 45 and 59. If all
cancers in patients under age 60 are considered, an overall
excess is seen [obs=47, expp=34.55, RR= 1.36, 95%
confidence interval (IC) 1.00-1.81, P = 0.050)]. This is
present in both males and females, but does not reach statis-
tical significance in these separate groups.
Table III shows that first-degree relatives not only have an
excess of carcinomas, which is present in both males and
females, but also have a significant excess of bone and soft-
tissue sarcomas (all the sarcomas were confirmed from
medical records). For individual sites the females have a
marked excess of breast cancer (3 of the 45 breast cancers
were unconfirmed, as the relative lived overseas). Considering
the breast cancers in more detail, daughters have a higher
risk of breast cancer than mothers and sisters, but these
relative risks are not statistically significantly different from
each other (mothers, obs = 13, exp = 4.66, RR = 2.79, 95%
CI 1.49-4.77, P = 0.002; sisters, obs = 26, exp = 10.8,
RR=2.41, 95% CI 1.57-3.53, P=0.00012; daughters,
obs=6, exp= 1.31, RR=4.58, 95% CI 1.68-9.97,
P = 0.004). However, if the female relatives are generally at a
higher relative risk of early-onset breast cancer, then the
possible raised risk in daughters could merely be a reflection
of their younger ages. Males alone have a significant excess
Table I All cancers by sex and type of relative
Number of Relative
relatives Observed Expected risk 95% CI P-value
First-degree relatives
Father 192 31 22.58 1.37 0.93-1.95 0.11
Brothers 495 52 41.09 1.27 0.95-1.66 0.11
Sons 372 1 3.25 0.31 0.01 -1.71 0.33
Male 1,059 84 66.92 1.26 1.00- 1.56 0.047
Mothers 244 25 19.92 1.26 0.81 -1.85 0.30
Sisters 447 49 38.26 1.28 0.95-1.69 0.091
Daughters 351 7 4.25 1.65 0.66-3.39 0.28
Female 1,042 81 62.43 1.30 1.04- 1.63 0.022
All 2,101 165 129.35 1.28 1.09-1.49 0.002
Second-degree relatives
Maternal male 612 42 35.28 1.19 0.86-1.61 0.30
Paternal male 424 26 22.31 1.17 0.76-1.71 0.49
Male 1,614 73 64.55 1.13 0.89-1.42 0.32
Maternal female 706 31 28.21 1.10 0.75-1.56 0.65
Paternal female 473 24 18.81 1.28 0.82-1.90 0.28
Female 1,661 63 54.82 1.15 0.88- 1.47 0.30
All 3,275 136 119.37 1.14 0.95- 1.34 0.14
Observed, observed number of cancers; expected, expected number of cancers; relative risk,
observed/expected, Cl. confidence interval for the relative risk.1S4 M.D. TEARE et al.
TaMA
Age at
diagnosis (years)
First-degree relatives
Under 15
Male
Female
All
15-29
Mak
Female
All
30-44
Male
Femak
All
45-59
Male
Femal
All
60-74
Male
Female
All
He I All ncers by age at iagnosis of the relative
Obs Exp RR 95% Cl P-vahle
I
0
(0)
I
1
1
(1)
2
2
20
(12)
22
22
20
(12)
42
58
40
(20)
98
Second-degree relatives
Under 15
Male 2
Female 0
(0)
Al 2
15-29
Mal
Female
All
30-44
Male
Female
All
45-59
Male
Female
All
60-74
Male
Female
All
1
(0)
2
2
5
(3)
7
18
18
(8)
36
0.31
0.24
(0)
0.55
1.06
0.99
(0.11)
2.05
3.36
5.58
(2.33)
8.94
18.02
19.98
(6.46)
37.99
44.18
35.64
(7.74)
79.82
0.69
0.53
(0)
1.22
1.54
1.39
(0.13)
2.93
2.33
4.04
(1.63)
6.37
11.60
12.36
(3.89)
24.03
50 48.12
39 36.28
(10) (8.00)
89 84.40
3.21
(-)
1.82
0.94
1.01
(9.39)
0.98
0.60
3.58
(5.15)
2.46
1.22
1.00
(1.86)
1.11
1.31
1.12
(2.58)
1.23
2.91
(-)
1.64
0.65
0.72
(-)
0.68
0.86
1.24
(1.84)
1.10
1.55
1.46
(2.06)
1.50
1.04
1.07
(1.25)
1.05
0.08-17.88
0.00-15.57
(-)
0.05-10.15
0.02-5.26
0.03-5.63
(10.23-50.65)
0.12-3.53
0.07-2.15
2.19-5.54
(2.66-9.00)
1.54-3.73
0.77-1.85
0.61-1.55
(0.96-3.24)
0.80-1.50
1.00-1.70
0.81-1.55
(1.58-2.71)
1.00-1.51
0.35-10.50
0.00-6.92
(-)
0.20-5.92
0.02-3.62
0.02-4.04
(0-28.38)
0.08-2.46
0.10-3.10
0.40-2.90
(0.38-5.38)
0.44-2.27
0.92-2.45
0.86-2.30
(0.89-4.05)
1.05-2.08
0.77-1.37
0.76-1.47
(0.60-2.30)
0.85-1.30
0.54
1.0
(-)
0.84
1.00
1.00
(0.20)
1.00
0.70
<0.0001
(0.0001)
0.00032
0.40
1.0
(0.065)
0.55
0.051
0.46
(0.00033)
0.046
0.49
0.95
(-)
0.69
1.00
1.00
(1.00)
0.88
1.00
0.75
(0.45)
0.90
0.10
0.16
(0.090)
0.03
0.82
0.69
(0.57)
0.65
Obs, observed number of cancers; Exp, expected number of cancers; KR, relative rsk
estinate, obs/exp; CL, confidence interval for the relative risk; numbers in brackets are breast
cancers only.
of carcinoma of lip, oral cavity and pharynx (two of these
were unconfirmed reports, but there is still a significant
excess if these are excluded), a non-significant excess of car-
cinoma of the colon and rectum, and an excess of other and
unspecified sites of borderline significnce (seven of these
were carcinomas of unknown or unspecified site; one was an
unconfirmed report).
Table IV lists observed and expected numbers of cancers
by morphological type in the second-degree relatives. There is
a highly significant excess in the other and unspecfied mor-
phological group. The observed 17 cancers here iclude two
neuroblastomas in young children; the remaining 15 are all
'cancer not otherwise specified', 10 ofwhich are unconfirmed
patient reports. There is still a sigificnt excess in this
category if the unconfirmed reports are ignored (P = 0.0068).
Although overall no excess of carcinomas is seen, there is a
borderline excess of breast carcinomas (P= 0.07, all
confirmed) and a significnt excess of kidney carcinoma (all
confirmed) for females. For the males there is a significant
deficit ofcarcinoma of the prostate and a siicant excess of
carcinoma of the trachea and lung (27 out of 34 confirmed).
The excess ofcarcinoma ofthe lip, oral cavity and pharynx is
not seen in the second-degree relatives, nor is the excess of
sarcomas.
Table V analyses risk ofcancers in the relatives by features
in the index patient. Figures for breast cancer alone are givenCANCER IN RELATIVES OF BREAST CANCER PATIENTS 18C
Tab III All cacers by morphological type in first-degree relatives
Obs Exp RR 95% Cl P-vahle
Carcinoma
Male
Female
All
76
72
148
58.30
55.34
113.64
1.30
1.30
1.30
1.03- 1.63
1.03- 1.65
1.12- 1.56
0.029
0.030
0.0018
Site of carcinoma
Bladder
Male
Female
All
Breast
Male
Female
Al
Cervix
Female
Colon
and rectum
Male
Female
All
Endometrium
Female
Kidney
Male
Female
All
Larynx
Male
Female
All
Lip, oral cavity
and pharynx
Male
Female
All
Ovary
Female
Pancreas
Male
Female
All
Prostate
(all ages)
Male
Stomach
Male
Female
All
Trachea and lung
Male
Femak
All
Uterus
Female
Other and
unspwfed
Male
Female
ALl
CNS twnour
Male
Female
All
Leukaemia and
lphoma
Male
Female
All
6
0
6
0
45
45
4.33
1.58
5.91
0.12
16.77
16.89
5 4.48
13
4
17
1.39
1.02
2.68
2.66
1.12
7.99 1.63
7.37 0.54
15.36 1.11
1 1.87 0.53
0
1
0
7
0
7
1.28
0.76
2.04
1.32
0.49
1.36 0.74
0.30 -
1.66 0.60
1.66
0.86
2.52
3.36
4
2
6
2.17
1.60
3.77
9 8.15
9
3
12
21
4
25
4.22
2.78
0.30
1.84
1.25
1.59
1.10
5.81 1.55
3.17 0.95
8.98 1.34
23.42 0.90
6.88 0.58
30.30 0.83
1 0.64
I11
5
16
2
3
4
4
8
1.56 0.04- 8.84
6.26 1.76
5.70 0.88
11.96 1.34
1.94
1.71
3.65
4.21
3.16
7.37
1.03
0.58
0.82
0.95
1.27
1.09
0.51- 3.02
0.00- 2.35
0.37- 2.22
0.00-30.74
1.97- 3.62
1.%- 3.59
0.36- 2.62
0.87- 2.79
0.15- 3.22
0.65- 1.78
0.01- 3.01
0.00- 2.88
0.03- 7.43
0.01- 2.74
0.01- 4.10
0.00-12.30
0.02- 3.36
1.71- 8.74
0.00- 4.34
1.12- 5.75
0.01- 1.67
0.50- 4.72
0.15- 4.57
0.59- 3.48
0.51- 2.11
0.71- 2.95
0.20- 2.80
0.69- 2.35
0.56- 1.37
0.16- 1.50
0.53- 1.22
0.53
0.42
1.00
1.0
<0.0001
<0.0001
0.92
0.13
0.30
0.72
0.89
0.56
1.0
0.79
1.0
1.0
1.0
0.0032
0.85
0.03
0.31
0.35
0.94
0.35
0.82
0.26
1.0
0.38
0.72
0.38
0.40
0.94
0.10
1.00
0.58
1.0
0.99
1.0
1.0
0.77
0.90
0.88- 3.15
0.29- 2.06
0.76- 2.17
0.12- 3.72
0.01- 3.28
0.17- 2.41
0.26- 2.43
0.35- 3.26
0.47- 2.15106 M.D. TEARE etal.
Table M (cont.)
Obs Exp RR 95% Cl P-valhe
Bone and soft-
tisue sarcoma
Male 2 0.68 2.94 0.36-10.61 0.30
Fcmaek 4 0.72 5.52 1.51-14.23 0.013
All 6 1.41 4.26 1.57- 9.33 0.0064
Melanoma
Male 0 0.54 - 0.00- 6.86 1.00
Femal 0 0.94 - 0.00- 3.93 0.78
Al 0 1.48 - 0.00- 2.50 0.46
Other and
unspecified
Male 0 1.25 - 0.00- 2.95 0.65
Femalk 0 0.55 - 0.00- 6.92 1.00
All 0 1.80 - 0.00- 2.04 0.35
Obs, observed number of cancers Exp, expected number of cancers RR, relative risk
estimate, obs/exp; Cl, confidence interval for RR.
Table IV All cancers by morphological type in swond-egree relatives
Obs Exp RR 95% Cl P-valu
Carcinoma
Male
Female
Al
52
52
104
Site of carcinoma
Blddker
Male
Female
Al
Breast
Male
Female
All
Cervix
Female
Colon
and rectum
Male
Female
Al
Endometrnum
Female
Kalncy
Male
Female
All
Larynx
Male
Female
AD
Lip, oral cavity
and pharynx
Male
Female
AD
Ovary
Female
Pancreas
Male
Female
An
Prostate
(all ages)
Male
Stomach
Mak
Female
All
2
3
0
21
21
56.06
48.02
104.08
4.04
1.40
5.44
0.11
13.58
13.69
3 3.73
4
6
10
7.63
6.97
14.60
0.93
1.08
1.00
0.25
1.43
0.55
1.55
1.53
0.80
0.52
0.86
0.69
0 1.60
0
5o
5
0
0
0
1
0
1
1.10
0.67
1.76
1.19
0.24
1.43
1.47
0.78
226
2 2.80
1
1
2
2.09
1.53
3.62
3 9.84
8
1
9
5.95
3.29
9.24
7.46
2.84
0.68
0.44
0.72
0.48
0.65
0.55
0.30
1.34
0.30
0.97
0.69- 1.22
0.37- 1.42
0.82- 1.22
0.01-
0.17-
0.11-
0.65
0.60
1.00
1.38
5.16
1.61
0.00-33.54
0.96- 2.36
0.95- 2.34
0.17- 2.35
0.14- 1.34
0.32- 1.87
0.33- 1.26
0.00- 2.30
0.00- 3.35
2.42-17.42
0.92- 6.62
0.00- 3.10
0.00-15.37
0.00- 2.58
0.02-
0.00-
0.01-
0.18
0.82
0.42
1.00
0.07
0.08
0.98
0.25
0.91
0.28
0.40
0.67
0.0012
0.068
0.61
1.00
0.48
3.79
4.73
2.47
0.09- 2.58
0.01-
0.02-
0.07-
2.67
3.64
1.99
0.06- 0.89
0.58- 2.65
0.01- 1.69
0.45- 1.85
1.00
0.91
0.68
0.94
0.76
1.00
0.60
0.021
0.50
0.32
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Table IV (cont.)
Obs Exp RR 95% Cl P-value
Trachea and lung
Mae 34 22.70 1.50 1.04- 2.09 0.032
Female 4 5.63 0.71 0.19- 1.82 0.68
All 38 28.32 1.34 0.95- 1.84 0.09
Uterus
Female 0 0.54 - 0.00- 6.83 1.00
Other and
unspeified
Male 2 5.73 0.35 0.04- 1.26 0.14
Female 7 5.26 1.33 0.54- 2.74 0.54
All 9 11.00 0.82 0.37- 1.55 0.68
CNS tumour
Male 3 1.79 1.76 0.35- 4.90 0.53
Female 2 1.58 1.27 0.15- 4.57 0.93
All 5 3.36 1.49 0.48- 3.47 0.50
Leukaemia and
lymphoma
Male 5 4.25 1.18 0.38- 2.75 0.84
Female 5 3.12 1.60 0.52- 3.74 0.41
All 10 7.37 1.36 0.65- 2.49 0.42
Bone and soft-
tLsue sarcoma
Male 0 0.73 - 0.00- 5.06 0.96
Female 0 0.73 - 0.00- 5.03 0.96
All 0 1.46 - 0.00- 2.52 0.46
Melanoma
Male 0 0.43 - 0.00- 8.55 1.0
Female 0 0.74 - 0.00- 5.01 0.96
All 0 1.17 - 0.00- 3.16 0.62
Other and
unspec#fied
Male 13 1.29 10.08 5.37-17.24 <0.0001
Female 4 0.63 6.37 1.74-16.30 0.0004
All 17 1.92 8.85 5.16-14.18 <0.0001
Obs, observed number of cancers; Exp, expected number of cance; RR, relative risk
estimate, obs/exp; Cl, confidence interval for RR.
in brackets. A higher risk to relatives of bilateral breast
cancer patients was not found in this series, and the risk was
equivalent to that in relatives of patients with unilateral
diseas. For breast caners alone, the risk to first-degree
relatives ofpatients with bilateral disease is similar to the risk
to first-degree relatives of patients with unilateral disease. In
second-degree relatives the risk is higher if the patient has
bilateral disease but the numbers in both groups are very
small. When age at diagnosis of the proband is considered,
both first- and second-degree relatives of patients diagnosed
between 40 and 49 have a higher risk (although not statis-
tically significantly higher) of cancers than relatives of
patients diagnosed at other ages, but a significant excess of
cancers in first-degree relatives ofpatients diagnosed at other
ages is also found (obs = 128, exp = 106.77, RR = 1.20, 95%
CI 1.11-1.45, P = 0.040). A similar pattern of risk emerges
when breast cancers alone are considered. It is notable that
the risk to relatives of patients diagnosed at less than 40
years did not differ from that in relatives of patients diag-
nosed over 50 years, although numbers were small in this
group.
A further breakdown of breast cancers alone by age at
diagnosis of the index patient is presented in Table VI. The
breast cancer incidence is shown by age group ofthe relative.
This table is of limited interest in itself as many of the cells
are empty, but it may be useful to compare with results from
other studies.
The more close relatives with breast cancer a woman has,
the higher her own risk of breast cancer (Claus et al., 1990).
If we therefore look only at families in which the patient has
at least one other first-degree relative with breast cancer, we
would expect the relative risk of breast cancers to be propor-
tionately higher than for all families. We might expect that
the risk for other cancers would also be raised. To evaluate
this hypothesis we analysed risks of cancers in those families
in which the index patient has a first-degree female relative
with breast cancer (Table VII). The relative risk here is lower
than that for all families, although for males alone it is the
same. For the second-degree relatives in these families
(obs=29, expp=20.86, RR= 1.39, 95% CI 0.93-1.35,
P = 0.11), the relative risk is higher but not statistically
significant.
The analysis of the first-degree relatives' cancers gave us
three distinct excess groups: sarcomas; carcinoma of breast
and lip; and carcinomas of the oral cavity and pharynx. The
cancer experience of second-degree relatives in families in
which the patient has at least one first-degree relative with
one of these cancers is summarised in Table VIII. There is a
borderline excess in the female relatives, but overall the
relative risk is unchanged. The individual sites that were in
excess for the second-degree relatives as a whole were also
examined. There is a higher risk of breast cancer in the
relatives of a patient with a first-degree relative affected, but
this is not statistically significant. The excess of carinoma of
the kidney in the female relatives is equally spread between
the two groups, as is the excess of trachea and lung car-
cinoma in males. This would suggest that the excesses of
cancers (except for carcinoma breast) are not clustering in the
same families.lM M.D. TEARE et al.
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Table VI Breast cancers by age of index patient and age of
relative
Age of index patient at diagnosis
Age group Under 40 40-49 50-59 60 plus
First-degree relative
Under 40
O 0 6 2 3
E 0.083 0.26 0.34 0.46
P 1.0 <0.0001 0.092 0.022
40-49
O 0 2 1 0
E 0.25 0.67 1.16 1.27
P 1.0 0.29 1.0 0.56
50-59
O 2 0 4 5
E 0.35 0.75 1.32 2.02
p 0.099 0.95 0.091 0.11
60-74
O 1 6 4 9
E 0.42 1.30 2.02 4.11
P 0.68 0.0045 0.29 0.049
Second-degree relative
Under 40
O 0 0 0 2
E 0.046 0.060 0.23 0.64
P 1.0 1.0 1.0 0.27
40-49
O 1 1 0 2
E 0.32 0.36 0.20 0.94
P 0.55 0.61 1.0 0.49
50-59
O 0 4 0 1
E 0.56 1.10 0.70 0.49
P 1.0 0.052 0.99 0.77
60-74
O 0 5 5 0
E 1.00 2.42 3.02 1.48
P 0.73 0.20 0.37 0.46
0, observed number of cancers; E, expected number ofcancers; P,
P-value.
Dio
The breast cancer probands in this series included all patients
treated with surgery at particular hospitals over a specific time period, and are therefore not subject to the selection
biases present in other series based on early age at diagnosis
or-amily history. There is a measurable excess risk of all
incident cancers to both male and female first-degree relatives
and a non-significant excess in the second-degree relatives.
Anderson et al. (1992) also found a similar, but non-signifi-
cant, result when looking at cancer deaths in first-degree relatives of young breast cancer patients. The excess of
cancers in the females is almost completely due to breast
cancers, but there is also a significant excess of bone and
soft-tissue sarcomas in the first-degree relatives and an excess
of carcinoma of the kidney in the second-degree female
cohort. Male first-degree relatives are at increased risk of carcinomas (of any or unspecified site), and the specific sites which are in excess differ in first- and second-degree
relatives.
The excess of cancers observed in second-degree relatives is
lower than in first-dege relatives. Applying the argument of
Risch (1990), assuing that breast cancer is the result of a
single susceptibility locus and the relative risk in first-degree relatives is 1.28, we would expect a risk in second-degree relatives of 1.14. This is in fact what we see, and the same
relationship holds true for males and females examined
separately. Following the same argument, we would expect the relative risk ofbreast cancer in second-degree relatives to
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Table VII Distnrbution of all cancers (and breast cancers) in the first-degree
daughter with breast cancere
relatives of cases with a mother, sister or
Number of Number offirst-
Relationship index patients degree relatives Observed Expected Relative risk 95% Cl P-value
All 63 383 22 20.32 1.08 0.68-1.64 0.71
(5) (2.64) (1.89) (0.61 -4.42) (0.25)
Male 206 14 10.58 1.32 0.72-2.22 0.35
(0) (0.01) (-) (-) (1.00)
Female 177 8 9.74 0.82 0.35- 1.62 0.78
(5) (2.63) (1.90) (0.62-4.44) (0.25)
Fathers 62 7 4.07 1.72 0.69-3.54 0.24
(0) (0.00) (-) (-) (1.0)
Brothers 90 7 6.13 1.14 0.46-2.35 0.83
(0) (0.01) (-) (-) (1.0)
Sons 54 0 0.38 - 0.00-9.71 1.00
(0) (0.00) (-) (-) (1.0)
Mothers 29 0 1.32 - 0.00-2.79 0.54
(0) (0.30) (-) (0.00-12.30) (1.00)
Sisters 92 8 7.79 1.03 0.44-2.02 1.00
(5) (2.13) (2.35) (0.76-5.48) (0.13)
Daughters 54 0 0.63 - 0.00-5.86 1.00
(0) (0.20) (-) (0.00- 18.44) (1.00)
aThe first relative to be diagnosed with a breast cancer was removed from the cohort. Observed, observed number of
cancers; Expected, expected number of cancers; Relative risk, observed expected; Cl, confidence interval for relative risk:
figures in brackets are for breast cancers only.
be 1.84. This is not so different from the observed 1.55.
However, all these observations are also consistent with a
polygenic model.
For all cancers the relative risk in first-degree relatives is
raised for all ages of index patient at diagnosis, but the risk
is markedly higher in relatives of patients diagnosed in the
age range 40-49. This age effect is also demonstrated in the
second-degree relatives.
We have found no evidence that relatives of women diag-
nosed with bilateral breast cancer are at increased risk of
breast cancer or cancer in general compared with relatives of
those women with unilateral breast cancer. This could be
because of the small number of patients with bilateral
disease, but other studies have found bilaterality not to be a
risk factor (Adami et al., 1981; Claus et al., 1990). It may
also have been due, in part, to our rigid definition of a
bilateral breast cancer patient. However, the status of
'bilateral' can only be a retrospective one. Some of the
women who were unilateral when eligible for our study may
subsequently develop another primary breast cancer. The
long term follow-up of these women and their relatives may
ultimately resolve this matter.
Tulinius et al. (1992) found an excess ofprostate, endomet-
nal and ovarian cancer in the relatives of women with breast
cancer. They had specifically examined these sites, and the
risks of cancers of other sites and histological groups were
not reported. Arason et al. (1993) found that prostate cancer
was frequently seen in breast cancer families selected for
linkage analyses. In first-degree relatives of our breast cancer
probands we did not see an excess of these cancers. However,
this analysis included only those cancers diagnosed after
1964, and if cancers occurring before 1965 are included we
observed 11 prostate carcinomas, five ovarian cancers (in-
cluding one germ cell tumour) and two endometrial car-
cinomas. Out of these 18 families, there were eight with
additional relatives with breast cancer. Four out of the five
ovarian cancers, but only I of the 11 prostate cancers,
appeared in patterns consistent with a dominant mode of
inheritance. This study has sufficient statistical power to
detect minimum relative risks of 1.84 for prostate carcinoma,
2.38 for ovarian carcinoma and of 3.20 for endometrial
carcinoma in the first-degree cohort. These 'detectable'
relative risks are all higher than those found by Tulinius et
al. (1992). Our study, therefore, lacks the power to confirm,
or refute, a relative risk ofthis magnitude, and it may be that
in a small number of families these cancers do tend to cluster
as a result of common aetiological factors.
There is an established excess risk of breast cancer for the
mothers of children with a sarcoma (Li et al., 1969; Birch et
al., 1984, 1990; Strong et al., 1987). Buirki et al. (1987) found
an excess of sarcomas in the brothers of breast cancer
patients. Familial aggregations of sarcoma, breast cancer and
other neoplasms at young ages is referred to as the Li-
Fraumeni syndrome. The excess of sarcoma seen in relatives
of women with breast cancer in the present series is compati-
ble with these previous observations. Recently, mutations in
the tumour-suppressor gene, p53, have been found in some
individuals whose families exhibit the Li-Fraumeni syndrome
(Malkin et al., 1990; Santibifiez-Koref et al., 1991). Among
the second-degree relatives of our patients there were two
children with neuroblastomas. It has recently been reported
that a germlne p53 mutation has been found in a patient
diagnosed with a neuroblastoma at age 1 year who subse-
quently developed breast cancer at age 32 years. Her mother
also had breast cancer (Malkin et al., 1992). Furthermore,
among series of breast cancer patients examined for p53
germlne mutations, four examples have been found, all
associated with a family history of breast and other cancers
(B0rreson et al., 1992; Prosser et al., 1992; Sidransky et al.,
1992). This is further evidence for breast cancer being a
heterogeneous disease, and the 'Li-Fraumeni' component is
actually measurable from a series such as ours.
The excess of sarcoma in first-degree relatives is not seen in
the second-degree relatives, but there a number of cancers
that could not be allocated to specific morphological groups
because of imprecise information. The lack of an excess of
particular types or sites here is not necessarily informative.
Other studies may have failed to detect an excess of sarcoma
because of inability to identify and calculate expected
numbers in this morphological group. Most cancer registries
classify patients according to the International Classification
of Diseases (ICD), which groups cancers by the site of the
tumour. ICD-O allows coding by specific histological type as
well as the site of the tumour, and we have access to
incidence rates based on ICD-O-coded cancer registry data
for the north-west of England.
The tables presented list around 250 statistical tests.
Although these are not all independent, we would expect110 M.D. TEARE et al.
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12-13 tests to be significant at the 5% level and 2-3 to be
significant at the 1% level, and these results would be due to
chance alone. In our analysis we see considerably more than
this, so although some of our significant results may be due
to chance, they are not simply an artifact of repeated test-
ing.
Recent developments in breast cancer linkage studies have
demonstrated strong evidence of tight linkage to the region
17q21 (Hall et al., 1990). The families that appeared to be
linked to this site were large, with predominantly early age at
onset. Easton et al. (1993) examined 214 breast cancer
families for linkage to 17q21 and, although all breast-ovarian
cancer families are consistent with linkage, there was
significant evidence of genetic heterogeneity amongst the
families for linkage to 17q21 and, although all breast-ovarian
cancer families are consistent with linkage, there was
this tightly linked gene to be very high (82% by age 70). If
the gene responsible for familial breast cancer is highly pene-
trant and can also predispose to other cancers, then, by
targeting those families with at least two first-degree relatives
with breast cancer, a much higher incidence of breast and
other cancers would be expected in this group. This is not
demonstrated by our analysis, and the present data would
support the hypothesis that a large proportion of breast
cancer could be caused either by shared environmental fac-
tors within families, giving the relatives a higher than
expected risk ofcancer, or by a relatively common predispos-
ing gene which has a low penetrance. A combination, or
interaction, of genetic and environmental factors could also
have a role.
Some families from our series were examined for linkage to
17q21, but the results were inconclusive (Teare et al., 1993).
The study by Skolnick et al. (1990) found evidence for a
common breast cancer gene, with low penetrance, responsible
for a considerable proportion of breast cancer. This is in
contrast to the majority of segregation analyses, which have
found familial clustering best described by a dominant rare
gene with high penetrance (Newman et al., 1988; Claus et al.,
1992; Iselius et al., 1992).
The present study has found that relatives of breast cancer
patients are at a higher risk of a variety of neoplasms than
the general population. This excess of cancers, including
breast cancer, is not limited to a small number of high-risk
familie but appears to be spread across many. Given the
evidence for genetic heterogeneity which has now come to
light convincingly through linkage analyses, the various
different single-gene models found by segregation analysis to
'best fit' familial breast cancer could be explained by ascer-
tainment bias, with each analysis correctly modelling the data
collected. Breast cancer probands are very often selected for
age at diagnosis or bilaterality. This could lead to an
overascertainment of a particular subtype of familial breast
cancer. Although our series is smaller than some other
studies, it is nevertheless substantial and unselected. Further-
more, an unusually high proportion of cancers in relatives
has been verified and fully documented, and many of the
breast cancers have been subjected to special histo-
pathological review. We are, therefore, in a good position to
model patterns of inheritance of breast cancer and to
examine the possibility that the excess of cancers at sites
other than breast segregate with a predisposing gene.
Segregation analyses on this data set are currently under way
to clarify this issue.
We are most grateful to Professor R.A. Sellwood for his support
with the project. Jillian M. Birch is a Cancer Research Campaign
Reader in Oncology. This researc:h was supported by the Cancer
Research Campaign.
ADAMI, H.O., HANSEN, J., YUNG, B. & RIMSTEN, AJ. (1981). Char-
acteristics of familial breast cancer in Sweden. Absence of rela-
tion to age and unilateral and bilateral disease. Cancer, 48,
1688-1695.
ANDERSON, D.E. (1971). Some characteristics of familial breast
cancer. Cancer, 28, 1500-1504.
ANDERSON, D.E. (1974). Genetic study of breast cancer.
Identification of a high risk group. Cancer, 34, 1090-1097.CANCER IN RELATIVES OF BREAST CANCER PATIENTlS 111
ANDERSON, D.E. & BADZIOCH, M.D. (1985). Risk of familial breast
cancer. Cancer, 56, 383-387.
ANDERSON, K-E., EASTON, D.F., MAITHEWS, F.E. & PETO, J.
(1992). Cancer mortality in the first degree relatives of young
breast cancer patients. Br. J. Cancer, 66, 599-602.
ANDRIEU, N., CLAVEL, F. & DEMENAIS, F. (1989). Familial suscep-
tibility to breast cancer. a complex inheritance. Int. J. Cancer, 44,
415-418.
ARASON, A., BARKARD6T-R, RB. & EGMSSON, V. (1993). Linkage
analysis of chromosome 17q markers and breast-ovarian cancer
in Icelandic families, and possible relationship to prostatic cancer.
Am. J. Hwn. Genet., 52, 711-717.
BIRCH, J.M., HARTLEY, AL., BLAIR, V., KELSEY, A.M., HARRIS, M.,
TEARE, M.D. & MORRIS-JONES, P.H. (1990). Cancer in the
famiies of children with soft tissue sarcoma. Cancer, 66,
2239-2248.
BIRCH, J.M., HARTLEY, A.L., MARSDEN, H.B., HARRIS, M. &
SWINDELL, R. (1984). Excess risk of breast cancer in the mothers
ofchildrn with soft tissue sarcomas. Br. J. Cancer, 49, 325-331.
B0RRESEN. A_-L., ANDERSEN, T.I., GARBER, J., BARBIER-PIRAUX,
N.. THORLACIUS. S.. EYFJORD, J.. OITSTAD, L., SMITH-
S0RESEN. B.. HOVIG. E.. MALKIN, D. & FRIEND, S.H. (1992).
Screening for germ line TP53 mutations in breast cancer patients.
Cancer Res., 52, 3234-3236.
BURUKI. N. GENCIK, A.. TORHORST, J.K.H., WEBER, W. &
MOLLER, H. (1987). Familial and histological analyses of 138
breast cancer patients. Br. Cancer Res. Treat., 10, 159-167.
CLAUS. E.B.. RISCH. NJ. & THOMPSON, W.D. (1990). Age at onset as
an indicator of familial risk of breast cancer. Am. J. Epidemiol.,
131, %1-972.
CLAUS. E.B.. RISCH. NJ. & THOMPSON. W.D. (1991). Genetic
analysis of breast cancer in the Caner and Steroid Hormone
Study. Am. J. Hum. Genet., 48, 232-242.
EASTON. D.F.. BISHOP, D.T.. FORD, D. & CROCKFORD, G.P. (1993).
Genetic linkage analysis in familial breast and ovarian cancer -
results from 214 families. Am. J. Hum. Genet., 52, 670-678.
EPILOG PLUS (1987). Epicenter Software. Epicenter Software,
Pasadena.
HALL, J.M., MING. K.. NEWMAN, B.. MORROW, J.E., ANDERSON,
L.A.. HUEY, B. & KING. M.-C. (1990). Linkag of early-onset
breast cancer to chromosome 17q21. Science, 250, 1684-1689.
HALL J.M.. FRIEDMAN, L.. GUENTHER, C., LEE, M.K., WEBER, J.L.,
BLACK, D.M.. KING, M.-C. (1992). Closing in on a breast cancer
gene on chromosome 17q. Am. J. Hum. Genet., 50,
1235-1242.
ISELIUS, L., LITTLER. M. & MORTON, N. (1992). Transmission of
breast cancer - a controversy resolved. Clin. Genet., 41,
211-217.
LI. F.P.. FRAUMENI, Jr. J.R. (1%9). Rhabdomyosarcoma in children:
Epidemiologic study and identification of a familial cancer syn-
drome. J. Natl Cancer Inst., 43, 1365-1373.
MALKIN. D., LI. F.P.. STRONG, L.C., FRAUMENI, Jr, J.F., NELSON,
C.E.. KIM, D.H.. KASSEL, J.. GRYKA, M.G., BISCHOFF, FL,
TAINSKY. M.A. & FRIEND, S.H. (1990). Germline p53 mutations
in a familial syndrome of breast cancer, sarcomas and other
neoplasms. Science, 250, 1233-1238.
MALKIN, D., JOLLY, K-W., BARBIER, N., LOOK, A.T., FRIEND, S.H.,
GEBHARDT, M.C., ANDERSEN, T.I., BORRESEN, A.-L., LI, F.P.,
GARBER, J. & STRONG, L.C. (1992). Germhne mutations of the
p53 tumor-suppressor gene in childrn and young adults with
second malignant neoplasms. N. Engl. J. Med., 326,
1309-1315.
NEWMAN, B, AUSTIN, MA., LEE, M. & KING, M.-C. (1988).
Inheritance of human breast cancer: evidence for autosomal
dominant tranission in high-risk families. Proc. Nail Acad. Sci.
USA, 85, 3044-3048.
NWENE, U. & SMITH, A. (1982). Assessing completeness of cancer
registration in the North-Western region of England by a method
of independent comparison. Br. J. Cancer, 46, 635-639.
PARKIN, D.M., LAARA, E. & MUIR, C.S. (1988). Estimates of the
worldwide frequency of sixteen major cancers in 1980. Int. J.
Cancer, 41, 184-197.
PROSSER, J., PORTER, D., COLES, C., CONDIE, A., THOMPSON, A.M.,
CHElTY, U., STEEL, C.M. & EVANS, HJ. (1992). Constitutional
p53 mutation in a non-Li-Fraumeni cancer family. Br. J. Cancer,
65, 527-528.
RISCH, N. (1990). Linkage strategies for genetically complex traits. I.
Multilocus models. Am. J. Hum. Genet., 46, 222-228.
SANTIBAREZ-KOREF, M.F., BIRCH, J.M., HARTLEY, A.L., MORRIS-
JONES, P.H., CRAFT, A.H., EDEN, T., CROWTHER, D., KEISEY,
A.M. & HARRIS, M. (1991). p53 germline mutations in Li-
Fraumeni syndrome. Lncet, 338, 1490-1491.
SIDRANSKY, D, TOKINO, T., HELZLSOUER, K., ZEHNBAUER, B.,
RAUSCH, G., SHELTON, B., PRESTIGIACOMO, L., VOGELSTEIN,
B. & DAVIDSON, N. (1992). Inherited p53 gene mutations in
breast cancer. Cancer Res., 52, 2984-2986.
SKOLNICK, M.H., CANNON-ALBRIGHT, L-A., GOLDGAR, D.E.,
WARD, J.H., MARSHALL CJ., SCHUMANN, G.B., HOGLE, H.,
MCWHORTER, W.P., WRIGHT, E.C., TRAN, T.D., BISHOP, D.T.,
KUSHNER, J.P. & EYRE, HJ. (1990). Inheritance of proliferative
breast disease in breast cancer kindreds. Science, 250,
1715-1720.
STRONG, L.C., STINE, M. & NORSTED, T.L. (1987). Cancer in sur-
vivors ofchildhood soft tissue sarcoma and their relatives. J. Natil
Cancer Inst., 79, 1213-1220.
TEARE, M.D., SANTIBANEZ-KOREF, M.F., WALLACE, SA., WHITE,
G.R.M., EVANS, D.G.R., BURNELL L-D., HARRIS, M., HOWELL,
A. & BIRCH, J.M. (1993). A linkage study in seven breast cancer
families. Am. J. Hwn. Genet., 52, 786-788.
TULINWUS, H., EGILSSON, V., OLAFSD6TTIR, G.H. & SIGVAL-
DASON, H. (1992). Risk of prostate, ovarian, and endometrial
cancer among relatives ofwomen with breast cancer. Br. Med. J.,
305, 855-857.
WILLLMS, W.R. & ANDERSON, D.E. (1984). Genetic epidemiology
of breast cancer segregation analysis of 200 Danish pedigrees.
Genet. Epidemiol., 1, 7-20.
WORLD HEALTH ORGANISATION (1976). ICD-O: International
Classification of Diseases for Oncology. World Health Organiza-
tion: Geneva.